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Abstract This study was planned
to investigate the economic impact
of headache on Turkish headache
sufferers attending a tertiary care
outpatient headache clinic.
A total of 937 headache patients
were included in this study
and questioned using
a questionnaire for the profile of
patients and headache, quality of
life of patients and economic
impact of headache. The median
total direct cost was found to be
88.0 USD and the median total
cost was 160.7 USD. The drug
treatment cost was the highest
item followed by the specialist
outpatient care cost. The average
lost and inefficient work/school
days was 1.5 (0–45) and 8.4
(0–100) days for one year.
It was shown that loss of produc-
tivity was higher for migraine
without aura group when com-
pared with the episodic and chron-
ic tension-type headache groups.
The results of this nationwide
university hospital based study
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Headache is one of the most common complaints, with a
lifetime prevalence of 95% for women and 90% for men
[1]. Migraine has a 1-year prevalence rate of 10%–12%
and a lifetime prevalence rate of 12%–18%, which is age-
and gender-dependent in community-based studies from
different parts of the world [2]. The lifetime prevalence of
migraine in Turkey was defined as 8% in males and 17%
in females in a nationwide epidemiological survey [3].
The prevalence of tension-type headache (TTH) was
found to be 31.7% in this survey [3]. The International
Headache Society (IHS) defined the criteria for all
headache types, mainly migraine and TTH [4], which is
pathophysiologically less understood but more frequent,
with a 1-year prevalence rate of 60%, than migraine [5].
Although treatment modalities have improved in recent
years, headache, particularly migraine, continues to be one
of the major health problems resulting in deterioration in
the quality of life (QoL), social life and work capacity of
sufferers and is an important economic burden on society
[6–8]. Headache sufferers were reported to experience
more restriction of their daily activities than patients with
depression, osteoarthritis, diabetes or hypertension [9].
Migraine, quadriplegia, psychosis and dementia are
accepted to be the most disabling diseases, which cause
maximum functional loss in patients’ life, by the World
Health Organization [10]. In a population survey, it was
found that half of migraine and TTH sufferers discontinued
normal activities during their attacks and most of them
required bed rest, preventing them from going to work or
working efficiently [11]. Headache sufferers are mostly at
their most productive ages. Migraine has its peak preva-
lence between 20 and 40 years of age. Such a common dis-
order in these very productive ages causing more disabili-
ty and restriction of life than many other severe diseases
has an important effect on the patients themselves, on soci-
ety and the economy as well. A number of studies in West
European and North American countries have shown this
effect, particularly the economic part [12–15]. In a large
epidemiological survey in France, total annual direct
healthcare costs were estimated to be 128 per individual
with migraine in 1999 and the total annual direct cost of
other forms of episodic headache was much lower at 28 per
individual [12]. Besides direct cost, indirect costs such as
lost productivity have been shown to be an important eco-
nomical burden on societies [16, 17]. As headache is such
a prevalent disorder, even the smallest economic loss per
person might have a great impact on the countries’
economies. This economic loss means a lot more to a
developing country than a developed country. The eco-
nomic burden of headache has mostly been investigated in
Western European or North American countries. This study
aimed to investigate the economic burden of headache on
the patient and the society in tertiary care headache centres
in a developing country.
Patients and methods
This was a cross-sectional epidemiological survey performed in
university hospitals located in the seven main geographical
regions of Turkey, between December 2001 and August 2002.
All centres started recruitment on different dates according to
the convenience of their schedules and the study was terminated
on 31 August. Different numbers of patients (30–120) were
recruited from headache centres.
All patients with a diagnosis of primary headache according
to the International Classification of Headache Disorders I [18]
were recruited randomly from outpatient headache clinics and
questioned for the profile of patients and headache according to
IHS criteria [18], treatment approaches and methods used for
diagnosis during the last year, QoL of patients and socioeco-
nomic impact of headache on the patients and society. The study
questionnaire was applied to the patients face to face by trained
research assistants at outpatient headache clinics. Before admin-
istering the questionnaire patients were asked if they had a
headache or not. Patients who had a headache were called on a
headache-free day in order to form a unique group and prevent
the effects of headache on patients’ cooperation.
This paper represents the results of the economic impact of
primary headaches on the patients and indirectly on the Turkish
economy.
The study data were collected using a questionnaire that con-
tains 50 questions. Details were given in the Patients and meth-
showed that headache, especially
migraine, has considerable eco-
nomic impact on patients.
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ods section of the first part of this study. Direct costs of
headache and cost of loss of productivity were the parameters
evaluated for this study.
Statistical methods for economic analysis
Five types of direct costs were used: primary care physi-
cian cost, cost for diagnostic work-up, specialist outpa-
tient care cost, drug treatment and hospital costs. These
were added to come up with the total direct cost of
headache for each patient. Primary care physician and
specialist outpatient care costs were calculated on the
basis of physician visits. Annual drug treatment costs
were calculated on the basis of monthly average analgesic
consumption and if a patient had received a prophylactic
treatment then the cost was added. Prophylactic treatment
was calculated according to the duration of the treatment
and prescribed drug cost. Indirect cost of headache was
calculated by the means of the loss of work days and loss
of efficiency at work. The total cost of headache to the
patient and the society was the sum of direct and indirect
costs. The ratio of total cost of headache per patient to
Gross National Product per capita estimated from the
Turkish State Institute of Statistics (3383 USD) was used
to calculate the ratio of costs to average income. The for-
eign exchange conversion rate of the Ministry of Finance
as of 1 March 2004 (1 USD: 1 314 825 Turkish Lira (TL))
was used to convert expenditure into United States
Dollars on which date the drug prices for 2004 were
released by the Ministry of Health. The applicable charges
for the same date for hospital stay, outpatient visits and
diagnostic work-up were retrieved from the price list
declared by the Ministry of Finance.
The indirect cost calculations used the current daily
minimum wage of 14.08 USD, announced by the govern-
ment officially twice a year, as the cost of the loss of a
work day. Two inefficient days at work were regarded as
a day absent from work.
Outcome data were classified according to types of
headache and several patient characteristics. Cost analysis
excluded one patient without adequate financial data.
Patients who suffer from more than one headache type
(other than combined headache) were excluded from the
cost analysis of the subgroups of headaches that they were
suffering from. Those patients have been analysed under
the heading of other headaches, which included cluster
headache, paroxysmal hemicrania, other infrequent pri-
mary headaches and multiple headache diagnosis. Chronic
daily headache was used for chronic migraine, 15 or more
migraine days in a month.
The differences between different patient subgroups
for cost and loss of productivity were analysed using the
Mann-Whitney U-test for dichotomous groups while
Kruskal-Wallis and Jonckheere-Terpstra tests were used
for groups with nominal and ordinal categories, respec-
tively. The level of statistical significance was defined as
p<0.05 for global comparisons. With the region and
headache type variables pairwise comparisons were per-
formed using Bonferroni correction which pushed the p-
value level of significance down to 0.00341 for multiple
comparisons.
The corresponding author’s university ethics commit-
tee approved the study and all patients gave informed con-
sent prior to their inclusion in the study.
Results
Patients’ profile
A total of 937 patients (81.5% female and 71% over 30
years of age) were included in the study. One patient was
excluded because of inadequate data. The headache profile
and QoL of patients were summarised in the first part of
this study. The frequency of severe headache was highest in
chronic daily (5 attacks/week and 16 attacks/month) and
chronic tension-type (5 attacks/week and 14 attacks/month)
headache. The number of headache days in a month were
20 days for chronic daily headache, 17 days for chronic
TTH and 13 days for combined headache sufferers.
Diagnosis and treatment of headache
The most common diagnostic tests were blood tests
(53.2%), plain X-ray (50.0%) and cranial CT scan
(44.5%) followed by cranial MR (21.1%).
Only 4% of the patients had been hospitalised for treat-
ment of headache. Over 93% of the subjects used anal-
gesics when they had headache, while 18% of all subjects
used analgesics regularly and 28% of all subjects used a
prophylactic agent regularly prescribed by a doctor in addi-
tion to the analgesics. The most common analgesic used for
headache attacks was naproxen sodium (77.0%). Naproxen
and paracetamol were also the most common analgesics
used regularly (26.4% and 17.4% respectively) (Table 1).
The most common prophylactic agents prescribed were
amitriptyline HCl (31.0%) and sertraline (21.0%).
About one-tenth (9%) of the whole study population
preferred alternative therapies to relieve headache. These
therapies included herbal drugs (33%), physiotherapy/regu-
lar massage (24%), acupuncture (18%), seeking help from
religious sources (16%) and relaxation techniques (14%).
78
Direct and total costs
As shown in Table 2, the average total direct cost per
patient was found to be 162.0 USD with a median of 88.0
USD (range: 7.6–1748.2). The average total cost (both
direct costs and indirect costs) was 242.2 USD with a
median of 160.7 USD (range: 7.6–1908.5). The average
ratio of total cost per patient to Gross National Product per
capita for Turkey, which is 3383 USD for 2003, is 7.2%
with a median of 4.7% (range: 0.2%–56.5%). The drug
treatment cost was the highest item (mean: 124.4 USD)
followed by the specialist outpatient care (mean: 18.1
USD) and diagnostic work-up (mean: 17.6 USD) costs. In
Table 3 all costs used to calculate direct and indirect costs
are given in detail.
Subgroup analysis showed that the direct costs signif-
icantly differed by the type of headache and region of res-
idence. Age group, gender and education level differences
were found to be statistically insignificant. Total direct
cost per patient was highest at 178.7 USD in the age group
of 20–29 years. Migraine with and without aura had the
highest average total direct costs per patient, which were
250.5 USD and 225.6 USD respectively. TTH groups
(episodic and chronic) had lower costs when compared to
both migraine with aura (MA) and migraine without aura
(MO). Southeastern Anatolia had higher costs when com-
pared to the other regions (Table 2).
The loss of productivity
The loss of productivity was studied with the lost and
inefficient work or school days in the last year. Loss of
work/school days ranged between 0 and 45 while
decreased work/school efficiency was reported to range
from 0 to 100 days for one year. The loss of work/school
days was highest in MO, CDH and combined headache
(migraine and TTH) groups. It was shown that loss of
work/school days was higher for MO when compared
with the episodic and chronic TTH groups.
The differences in inefficient work or school days
among groups were only statistically significant
between the episodic TTH and combined headache
groups, the former causing the least and the latter caus-
ing the highest number of inefficient work/school days
(Table 3).
Discussion
In the second part of this large university hospital based
cross-sectional survey investigating tertiary care
headache patients’ profile, characteristics of primary
headaches and the effects of headaches on QoL, we pri-
marily focused on the economic impact of headache on
patients and society.
Although there is a great heterogeneity of costs of
work/school days in Turkey, we calculated the indirect
costs of headache as loss of productivity and loss of
work/school days/year, regarding minimum wage in
Turkey, which is approximately 14.08 USD/work day,
announced by the government officially twice a year. We
calculated the direct cost of headache, which is the sum of
subcomponents like primary care physician costs, cost for
diagnostic work-up, specialist outpatient care costs, drug
treatment costs and hospital costs.
The average total direct cost per patient was found to
be 162.0 USD, with a median of 88.0 USD (range:
7.6–1748.2). Von Korff et al. [19] defined the cost of
headache in a good-outcome group as 307 USD and in a
poor-outcome group as 750 USD per patient per year.
When compared to a French study, our total direct cost
for migraine is nearly two times higher [12]. In Spain,
another Mediterranean country, both direct and indirect
Table 1 The analgesics used by patients for individual headache attacks and on a regular basis, either prescribed by physicians or obtained
by patients themselves (n=936)
Analgesic Used only for individual headache attacks (%) On a regular basis (%)
Naproxen Na 77.0 26.4
Paracetamol 74.0 17.4
Metamizol Na 35.0 15.5
Flurbiprophen 16.0 18.6
Ergotamine 15.0 11.8
Acetyl salicylic acid 12.0 13.7





total costs were higher [20]. Badia et al. [20] reported
that the highest item in direct cost was primary care vis-
its, but it was medication in our study. The relatively
lower direct costs of headache in our study might be
explained by the cheapness of the costs of diagnostic
and treatment tools in Turkey and general lower tenden-
cy of Turkish patients to seek medical care. The expla-
nations for the large range of direct costs in this study
are the heterogeneity of severity of headache and prob-
ably socioeconomic level of the studied population.
This hypothesis was supported by the findings of the
significant difference in the direct costs of headache
regarding the type of headache and region of residence.
Patients with MA and MO were defined to have higher
costs compared to TTH. The highest total cost for
headache was in the Southeastern region. The education
level in this region is the lowest in Turkey. This might
have resulted in inappropriate use of medication and
healthcare facilities, which might have resulted in high-
er costs. In the western part of Turkey, total cost is in the
Table 2 Total direct costs by patient subgroups
n Mean (SD) Median (range) Significance
All patients 936 162.0 (225.9) 88.0  (7.6–1748.2)
Age group <20 53 101.1 (124.9) 31.5  1(7.6–566.3) p=0.42, Jonckheere-Terpstra 
test for trend
20–29 247 178.7 (265.1) 88.0  (7.6–1450.1)
30–39 277 164.5 (203.4) 95.1  (7.6–1219.0)
40–49 246 156.9 (206.5) 92.4  (7.6–1490.0)
50–59 93 162.3 (276.4) 56.8  (7.6–1748.2)
60–64 20 146.8 (152.2) 100.8  1(7.6–647.9)
Gender Female 763 165.5 (227.5) 91.3  (7.6–1748.2) p=0.17, Mann-Whitney 
U-test
Male 173 146.8 (218.9) 79.0  (7.6–1450.1)
Geographical Southern 129 125.6 (184.5) 53.2  (7.6–1108.3) p<0.001, Mann-Whitney 
regions U with Bonferroni correction*
Southeastern 124 222.6 (154.2) 258.8  1(7.6–833.7)
Northwestern 335 165.8 (250.0) 83.5  (7.6–1748.2)
Western 148 140.3 (216.6) 73.0  (7.6–1207.0)
Central 130 200.9 (288.5) 96.2  (7.6–1490.0)
Northern 70 77.5 (87.5) 44.9  1(7.6–373.8)
Marital status Married 700 163.2 (220.3) 91.3  (7.6–1748.2) p=0.28, Kruskal-Wallis test
Single 199 164.3 (251.9) 77.6  (7.6–1450.1)
Divorced/widowed 37 128.6 (181.6) 53.2  1(7.6–911.4)
Education No formal education 59 200.3 (289.4) 125.5  (7.6–1748.2) p=0.53, Jonckheere-Terpstra 
test for trend
Primary school 231 143.2 (211.9) 71.5  (7.6–1232.0)
Secondary school 107 185.6 (232.6) 128.3  (7.6–1490.0)
High–school 282 164.9 (219.7) 96.6  (7.6–1224.5)
University 248 158.3 (227.0) 84.6  (7.6–1450.1)
Type of headache Episodic tension 159 93.0 (115.1) 39.1  1(7.6–833.7) p<0.001, Kruskal-Wallis 
test**
Chronic tension 168 104.8 (122.3) 53.5  1(7.6–833.7)
MA 72 225.6 (206.8) 183.3  1(7.6–979.1)
MO 241 250.5 (290.4) 160.5  (7.6–1490.0)
Combined headache 126 197.4 (281.4) 109.8  (7.6–1219.0)
CDH 51 120.7 (110.7) 105.3  1(7.6–566.3)
Other 119 97.8 (208.2) 22.8  (7.6–1748.2)
SD, standard deviation; MA, migraine with aura; MO, migraine without aura; CDH, chronic daily headache
*p<0.001 for Southeastern vs. all other regions with Mann-Whitney U-test; **p<0.001 for episodic tension vs. MA, episodic tension vs.

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































middle range. These regions are the most developed
regions of Turkey. Education level is higher than other
regions. As seen in the education-total cost relation,
education has a decreasing effect on the total cost of
headache. Highly educated headache patients might
avoid trigger factors and might have received better
headache management.
In this study, the drug treatment cost was the highest
item (mean: 124.4 USD) followed by the specialist outpa-
tient care (mean: 18.1 USD) and diagnostic work-up
(mean: 17.6 USD) costs. This study was conducted in the
university hospitals’ “tertiary-care” headache outpatient
clinics. In Turkey, most of the patients of the university
hospitals are covered by social security institutions of the
state. The price list for the medical services of these uni-
versity hospitals are determined by the Ministry of
Finance, which the university hospitals have to obey. In
order to lower the medical expenses, the Ministry of
Finance generally declares lower prices for medical ser-
vices. The price list of medical drugs is also declared by
the official authorities. However, drug prices are relative-
ly very high when compared to the medical services given
in the university hospitals. Therefore, the costs of special-
ist outpatient care and diagnostic work-up were nearly
one-seventh of drug treatment cost. Social security insti-
tutions cover a great percentage of health expenses in
Turkey. The reimbursement rate for hospitalisation, inves-
tigation and doctor visits is 100%. For medication this is
80% for working patients and 100% for retired patients.
Therefore, these high reimbursement rates increase the
economic burden on society.
It has been found that headache is a considerable
economic burden regarding loss of productivity [16]. In
this study, the mean loss of work/school days was
1.5±5.1 days/year/patient and the mean inefficient
work/school days was 8.4±17.5 days/year/patient.
Compared to the study of Stewart et al. [17], which
reported lost productive time for patients with headache
as 3.5±0.1 h/week, our results indicated very much less
loss of productivity. In a population-based diary study,
migraineurs experienced an average of 3.0 lost work
days/year, which was also higher than our findings
[21]. Bigal et al. [22] reported the mean number of total
lost working hours per month due to migraine as 6.5 in
a public Brazilian hospital. These variabilities might be
explained by the different designs of studies and socio-
cultural differences between populations. The work
attendance of Turkish patients despite headache seems
higher. The great difference between lost and ineffi-
cient work/school days supports this suggestion. In a
study on Swedish patients the ratio of going to work
despite headache among patients with headache was
50% [23].
As expected, chronic TTH costs were higher than
episodic headaches. The higher loss of productivity in
chronic TTH had an important effect on the total cost. It
was shown that indirect costs as loss of productivity at
work/school days were higher for MO when compared
with the episodic and chronic TTH groups, which was
similar to the difference for direct cost. Mean total direct
cost in the MO group was higher than in MA. However,
this difference was insignificant. The differences in ineffi-
cient work/school days among groups were only statisti-
cally significant between the episodic tension-type and
combined headache groups, the former causing the least
and the latter causing the highest number of inefficient
work/school days.
If indirect costs, calculated regarding minimum wage
in Turkey (14.08 USD/day), were added to direct cost, the
average total cost of migraine was found to be 242.2 USD,
with a median of 160.7 USD (range: 7.6–1908.5). Many
previous studies have investigated the direct and indirect
costs of headache [12–15, 24]. These studies demonstrat-
ed that the indirect costs of headache were more than the
direct costs. In this study, the direct cost of migraine
seems higher than indirect costs, which might be
explained by the low minimum wage in Turkey.
In order to overcome comparison difficulties between
studies and to reach a standard value to overcome the low
prices in Turkey, we calculated the average ratio of total
cost of headache per patient to Gross National Product per
capita for Turkey, which is 3383 USD for 2003. The aver-
age ratio was 7.2%, with a median of 4.7% (range:
0.2%–56.5%), which is strikingly high.
This study showed that headache, particularly
migraine, might have an important economic impact on
the patient and society. Therefore, in order to reduce the
economic burden of migraine, proper diagnosis and treat-
ment of migraine becomes even more important.
Unfortunately, only 31% of migraineurs had sought help
in their lifetime. Of those, 73% were properly diagnosed
as migraine and 46% had a prescription medication [25].
Therefore, increasing awareness about migraine and prop-
er diagnosis and treatment of migraine not only improves
the patients’ quality of life but helps to alleviate the eco-
nomic burden as well.
As a conclusion, the results of this study, which is the
first large university hospital based study investigating the
direct and indirect costs of headache in Turkey, showed
that headache has a considerable economic impact on
headache sufferers and society. Therefore, it should be
regarded as a public health problem and measures should
be taken to reduce its impact on patients and society.
Acknowledgement Merck Sharpe Dohme, Turkey, provided
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